Manhattan HIV/Hepatology Brain Bank

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00300209

Enrollment

187

Registered

2006-03-08

Start date

1998-09-30

Completion date

2002-06-30

Last updated

2016-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis, HIV

Brief summary

Description: The Manhattan HIV/Hepatology Brain Bank (MHBB) was established in 1998 as a resource for the AIDS research community. The MHBB was created to act as a center for the provision of pre- and post-mortem tissues and body fluids from HIV infected persons. It has recently expanded its goals to assist in the elucidation of liver disease-induced nervous system disorders. The MHBB is dedicated to improving the understanding of HIV and Hepatitis C and thereby, improving the lives of patients living with HIV and/or Hepatitis C. Participation is voluntary and can be stopped at any time. Benefits: This is an observational study; no experimental procedures, devices or drugs are used. All enrolled patients undergo regular examinations by physicians, nurses, and neuropsychologists who specialize in the problems that HIV and HCV can cause. Taking part in this study may result in the detection of brain, muscle, or spinal cord disease for which treatments may be available. Participants may receive no direct benefit from this study. However, knowledge gained from this research may, in the future, help others who suffer from HIV/AIDS and/or liver disease. Participants agree to autopsy and organ donation upon demise by signing an Anatomical Gift Consent document.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

CD4 \< 50 on two occasions \>12 weeks apart. Hemoglobin \<10 G/dL. Albumin \<3.2 G/dL. CMV end-organ disease Disseminated MAC PML AIDS Dementia Complex Wasting (\>30% of lean body mass) Visceral Kaposi's sarcoma Lymphoma-systemic of CNS CHF Major systemic illness with poor prognosis (as determined by primary physician).

Exclusion criteria

\- \<18 years old Not willing to sign an Anatomical Gift Consent for autopsy and organ donation upon demise.

Design outcomes

Primary

Measure	Time frame	Description
Viral Load blood level	Baseline	Plasma viral load level

Secondary

Measure	Time frame
CD4 cell blood level	Baseline

Countries

United States

Outcome results